Source-grounded facts extracted from CEL SCI CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CEL SCI CORP entered into Placement Agency Agreement with ThinkEquity LLC valued at $2,500,000 (effective 2026-06-14).
“On June 14, 2026, CEL-SCI Corporation, a Colorado corporation (the "Company"), entered into a Placement Agency Agreement with ThinkEquity LLC (the "Placement Agent") relating to the sale and issuance of 2,500,000 shares of the Company’s common stock, at an offering price of $1.00 per share (the "Shares").”
CEL SCI CORP entered into a license with Amarox.
“the Company issued a press release, filed as Exhibit 99, concerning a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential commercialization of Multikine (Leukocyte Interleukin, Injection) in the treatment of head and neck cancer in Saudi Arabia, with an optional extension for the Gulf Cooperation Council (GCC) countries including Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates.”
CEL SCI CORP entered into Placement Agency Agreement with ThinkEquity LLC valued at $7,200,000 gross proceeds from offering of 6,000,000 shares at $1.20 per share (effective 2026-05-11).
“On May 11, 2026, CEL-SCI Corporation, a Colorado corporation (the “Company”), entered into a Placement Agency Agreement with ThinkEquity LLC (the “Placement Agent”) relating to the sale and issuance of 6,000,000 shares of the Company’s common stock, at an offering price of $1.20 per share (the “Shares”).”
CEL SCI CORP issued securities.
“On October 30, 2025, the Board of Directors of CEL-SCI Corporation (the "Company") amended its Shareholder Rights Agreement, originally adopted on November 7, 2007, to provide that the Shareholder Rights Agreement will now expire on October 30, 2030.”
Patricia B. Prichep changed role as Chief Financial and Operations Officer at CEL SCI CORP.
“Patricia B. Prichep, CEL-SCI’s current senior Vice President of Operations, has assumed the duties of CEL-SCI’s Chief Financial and Operations Officer, effective November 13, 2024.”
Mario Gobbo was appointed as Director at CEL SCI CORP.
“On April 19, 2024, CEL-SCI Corporation appointed Mario Gobbo to its Board of Directors.”
CEL SCI CORP shareholders approved Ratify appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending September 30, 2024 at the 2024-04-19 meeting.
“to ratify the appointment of BDO USA, P.C. as CEL-SCI’s independent registered public accounting firm for the fiscal year ending September 30, 2024”
CEL SCI CORP shareholders approved Adoption of CEL-SCI’s 2024 Non-Qualified Stock Option Plan at the 2024-04-19 meeting.
“the adoption of CEL-SCI’s 2024 Non-Qualified Stock Option Plan”
CEL SCI CORP shareholders approved Election of Directors at the 2024-04-19 meeting.
“The annual meeting of CEL-SCI’s shareholders was held on April 19, 2024. At the meeting the following persons were elected as directors for the upcoming year: Name Votes For Votes Against Broker Non-Votes Geert Kersten 12,694,041 1,431,331 12,800,581 Bruno Baillavoine 12,035,656 2,089,716 12,800,581 Robert Watson 12,272,038 1,853,334 12,800,581”
CEL SCI CORP entered into Underwriting Agreement with ThinkEquity LLC valued at $7,750,000 (effective 2024-02-08).
“On February 8, 2024, CEL-SCI Corporation, a Colorado corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC”
CEL SCI CORP entered into Underwriting Agreement with ThinkEquity LLC valued at $4,980,000 (effective 2023-11-15).
“On November 15, 2023, CEL-SCI Corporation, a Colorado corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC, as the representative (the “Representative”) of the several underwriters named therein, if any (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 2,490,000 shares of the Company’s common stock, par value $0.01 per share, to a single investor at an offering price of $2.00 per share (the “Shares”).”
CEL SCI CORP entered into Underwriting Agreement with ThinkEquity, LLC as Representative of the several underwriters valued at approximately $4,500,000 (effective 2023-07-17).
“On July 17, 2023, CEL-SCI Corporation (the “Company”) entered into an Underwriting Agreement with ThinkEquity, LLC as Representative of the several underwriters, pursuant to which the Company agreed to issue and sell 2,500,000 shares of common stock at a public offering price of $2.00 per share. The Company expects to receive approximately $4,500,000 in net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses.”
CEL SCI CORP shareholders approved Ratification of appointment of BDO USA, LLP as independent registered public accounting firm at the 2023-05-23 meeting.
“(6) 19,101,272 1,829,100 694,769 -”
CEL SCI CORP shareholders approved Non-binding advisory vote on frequency of advisory vote on executive compensation at the 2023-05-23 meeting.
“Proposal 1 Year 2 Years 3 Years Abstain Broker Non-Votes (5) 3,740,819 232,413 5,165,164 1,355,978 11,130,767”
CEL SCI CORP shareholders approved Non-binding advisory vote on compensation of executive officers at the 2023-05-23 meeting.
“(4) 7,983,457 2,098,246 412,671 11,130,767”
CEL SCI CORP shareholders approved Adoption of CEL-SCI's 2023 Stock Bonus Plan at the 2023-05-23 meeting.
“(3) 7,179,948 2,936,609 377,817 11,130,767”
CEL SCI CORP shareholders approved Adoption of CEL-SCI's 2023 Non-Qualified Stock Option Plan at the 2023-05-23 meeting.
“(2) 7,391,922 2,683,385 419,067 11,130,767”
CEL SCI CORP shareholders approved Election of Directors at the 2023-05-23 meeting.
“Name Votes For Votes Against Broker Non-Votes Geert Kersten 8,636,412 1,857,962 11,130,767 Peter Young 8,324,014 2,170,360 11,130,767 Bruno Baillavoine 8,957,286 1,537,088 11,130,767 Robert Watson 8,958,603 1,535,771 11,130,767 Gail Naughton 9,537,048 957,326 11,130,767”
CEL SCI CORP entered into Underwriting Agreement with Spartan Capital Securities, LLC valued at approximately $1,119,000 (effective 2023-04-27).
“On April 27, 2023, CEL-SCI Corporation (the “Company”) entered into an Underwriting Agreement with Spartan Capital Securities, LLC as Representative of the several underwriters, pursuant to which the Company agreed to issue and sell 794,117 shares of common stock at a public offering price of $1.70 per share.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.